HSV as A Platform for the Generation of Retargeted, Armed, and Reporter-Expressing Oncolytic Viruses

Recombinant Parvoviruses Armed to Deliver CXCL4L1 and CXCL10 Are Impaired in Their Antiangiogenic and Antitumoral Effects in a Kaposi Sarcoma Tumor Model Due To the Chemokines' Interference with the Virus Cycle

(2017) Christiane Dinsart et al.   HUMAN GENE THERAPY

A Strategy for Cultivation of Retargeted Oncolytic Herpes Simplex Viruses in Non-cancer Cells

(2017) Valerio Leoni et al.   JOURNAL OF VIROLOGY

Simultaneous Insertion of Two Ligands in gD for Cultivation of Oncolytic Herpes Simplex Viruses in Noncancer Cells and Retargeting to Cancer Receptors

(2017) Valerio Leoni et al.   JOURNAL OF VIROLOGY

Dual Ligand Insertion in gB and gD of Oncolytic Herpes Simplex Viruses for Retargeting to a Producer Vero Cell Line and to Cancer Cells

(2017) Biljana Petrovic et al.   JOURNAL OF VIROLOGY

Insertion of a ligand to HER2 in gB retargets HSV tropism and obviates the need for activation of the other entry glycoproteins

(2017) Biljana Petrovic et al.   PLoS Pathogens

How to develop viruses into anticancer weapons

(2017) Roberto Cattaneo et al.   PLoS Pathogens

Oncolytic measles virus encoding interleukin-12 mediates potent antitumor effects through T cell activation

(2017) Rūta Veinalde et al.   OncoImmunology

TGF-β Inhibition Improves Oncolytic Herpes Viroimmunotherapy in Murine Models of Rhabdomyosarcoma

(2017) Brian Hutzen et al.   Molecular Therapy-Oncolytics

Immune System, Friend or Foe of Oncolytic Virotherapy?

(2017) Anna C. Filley et al.   Frontiers in Oncology

Oncolytic viruses—immunotherapeutics on the rise

(2016) Brian A. Keller et al.   JOURNAL OF MOLECULAR MEDICINE-JMM

To Infection and Beyond: The Multi-Pronged Anti-Cancer Mechanisms of Oncolytic Viruses

(2016) Kevin Cassady et al.   Viruses-Basel

Retargeting Strategies for Oncolytic Herpes Simplex Viruses

(2016) Gabriella Campadelli-Fiume et al.   Viruses-Basel

IL-12 Expressing oncolytic herpes simplex virus promotes anti-tumor activity and immunologic control of metastatic ovarian cancer in mice

(2016) Eric D. Thomas et al.   Journal of Ovarian Research

Noninvasive Monitoring of Glioma Growth in the Mouse

(2016) Francesco Alessandrini et al.   Journal of Cancer

Design of a Phase I Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma

(2016) Daxa M. Patel et al.   Human Gene Therapy Clinical Development

Systemic versus local responses in melanoma patients treated with talimogene laherparepvec from a multi-institutional phase II study

(2016) Howard L. Kaufman et al.   Journal for ImmunoTherapy of Cancer

The histone demethylase KDM5A is a key factor for the resistance to temozolomide in glioblastoma

(2015) Barbara Banelli et al.   CELL CYCLE

Neuroblastomas vary widely in their sensitivities to herpes simplex virotherapy unrelated to virus receptors and susceptibility

(2015) P-Y Wang et al.   GENE THERAPY

Epstein-Barr virus infection induces miR-21 in terminally differentiated malignant B cells

(2015) Eleni Anastasiadou et al.   INTERNATIONAL JOURNAL OF CANCER

Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma

(2015) Robert H.I. Andtbacka et al.   JOURNAL OF CLINICAL ONCOLOGY

Use of miRNA Response Sequences to Block Off-target Replication and Increase the Safety of an Unattenuated, Glioblastoma-targeted Oncolytic HSV

(2015) Lucia Mazzacurati et al.   MOLECULAR THERAPY

Cancer-fighting viruses win approval

(2015) Heidi Ledford   NATURE

Systemic delivery of HER2-retargeted oncolytic-HSV by mesenchymal stromal cells protects from lung and brain metastases

(2015) Valerio Leoni et al.   Oncotarget

The Engineering of a Novel Ligand in gH Confers to HSV an Expanded Tropism Independent of gD Activation by Its Receptors

(2015) Valentina Gatta et al.   PLoS Pathogens

Combination of Oncolytic Herpes Simplex Viruses Armed with Angiostatin and IL-12 Enhances Antitumor Efficacy in Human Glioblastoma Models

(2015) Wei Zhang et al.   NEOPLASIA

Oncolytic viruses as therapeutic cancer vaccines

(2013) David L Bartlett et al.   Molecular Cancer

New viruses for cancer therapy: meeting clinical needs

(2013) Tanner S. Miest et al.   NATURE REVIEWS MICROBIOLOGY

Production of Bioactive Soluble Interleukin-15 in Complex with Interleukin-15 Receptor Alpha from a Conditionally-Replicating Oncolytic HSV-1

(2013) David C. Gaston et al.   PLoS One

Viral therapy of glioblastoma multiforme

(2013) R. J. Whitley et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Preclinical Therapy of Disseminated HER-2+ Ovarian and Breast Carcinomas with a HER-2-Retargeted Oncolytic Herpesvirus

(2013) Patrizia Nanni et al.   PLoS Pathogens

Efficacy of HER2 retargeted herpes simplex virus as therapy for high-grade glioma in immunocompetent mice

(2012) E Reisoli et al.   CANCER GENE THERAPY

Anti-Epidermal Growth Factor Receptor (EGFR) Antibodies Overcome Resistance of Ovarian Cancer Cells to Targeted Therapy and Natural Cytotoxicity

(2012) Nina Gottschalk et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Replication-competent Herpes Simplex Virus Retargeted to HER2 as Therapy for High-grade Glioma

(2012) Eleonora Gambini et al.   MOLECULAR THERAPY

Effective Treatment of an Orthotopic Xenograft Model of Human Glioblastoma Using an EGFR-retargeted Oncolytic Herpes Simplex Virus

(2012) Hiroaki Uchida et al.   MOLECULAR THERAPY

Oncolytic virotherapy

(2012) Stephen J Russell et al.   NATURE BIOTECHNOLOGY

Single cell detection of latent cytomegalovirus reactivation in host tissue

(2011) A. Marquardt et al.   JOURNAL OF GENERAL VIROLOGY

Rethinking herpes simplex virus: the way to oncolytic agents

(2011) Gabriella Campadelli-Fiume et al.   REVIEWS IN MEDICAL VIROLOGY

Phase I/II Study of Oncolytic HSVGM-CSF in Combination with Radiotherapy and Cisplatin in Untreated Stage III/IV Squamous Cell Cancer of the Head and Neck

(2010) K. J. Harrington et al.   CLINICAL CANCER RESEARCH

OPTIM trial: a Phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanoma

(2010) Howard L Kaufman et al.   Future Oncology

Phase I/II Study of Oncolytic Herpes Simplex Virus NV1020 in Patients with Extensively Pretreated Refractory Colorectal Cancer Metastatic to the Liver

(2010) Sunil K. Geevarghese et al.   HUMAN GENE THERAPY

A Double Mutation in Glycoprotein gB Compensates for Ineffective gD-Dependent Initiation of Herpes Simplex Virus Type 1 Infection

(2010) H. Uchida et al.   JOURNAL OF VIROLOGY

Transcriptional and Translational Dual-regulated Oncolytic Herpes Simplex Virus Type 1 for Targeting Prostate Tumors

(2010) Cleo YF Lee et al.   MOLECULAR THERAPY

Host Lymphodepletion Enhances the Therapeutic Activity of an Oncolytic Vaccinia Virus Expressing 4-1BB Ligand

(2009) H. S. Kim et al.   CANCER RESEARCH

The EGFRvIII variant in glioblastoma multiforme

(2009) Hui K. Gan et al.   JOURNAL OF CLINICAL NEUROSCIENCE

Therapeutic and Tumor-specific Immunity Induced by Combination of Dendritic Cells and Oncolytic Adenovirus Expressing IL-12 and 4-1BBL

(2009) Jing-Hua Huang et al.   MOLECULAR THERAPY

Molecular Profiling of Breast Cancer Cell Lines Defines Relevant Tumor Models and Provides a Resource for Cancer Gene Discovery

(2009) Jessica Kao et al.   PLoS One

Inhibition of human tumor growth in mice by an oncolytic herpes simplex virus designed to target solely HER-2-positive cells

(2009) L. Menotti et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Construction of a Fully Retargeted Herpes Simplex Virus 1 Recombinant Capable of Entering Cells Solely via Human Epidermal Growth Factor Receptor 2

(2008) L. Menotti et al.   JOURNAL OF VIROLOGY

Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded

(2008) Roberto Cattaneo et al.   NATURE REVIEWS MICROBIOLOGY